YLYanrong Lv

Yanrong Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanrong Lv has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Haidong Gao

    Department of Breast Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China

    2 shared publications
  • Ke Dong

    Department of General Surgery, Qilu Hospital of Shandong University (Qingdao), Qingdao, China

    2 shared publications
  • Chenchen Geng

    Department of Ultrasound, Qilu Hospital of Shandong University (Qingdao), Qingdao, China

    1 shared publication
  • Haiyun Song

    Department of Pathology, Qilu Hospital (Qingdao) of Shandong University, Qingdao 266000, China

    1 shared publication
  • Junhua An

    Department of General Surgery, Qilu Hospital of Shandong University (Qingdao), Qingdao, China

    1 shared publication
  • Ke Dong

    Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China

    1 shared publication

Latest Publications

  • Open Access

    OTUD3 inhibits breast cancer cell metastasis by regulating TGF-β pathway through deubiquitinating SMAD7

    by Chenchen Geng, Ke Dong, Junhua An, Ziqian Liu, Qianqian Zhao, Yanrong Lv

    Breast cancer (BRCA) is the most common malignant tumor in women, and distant metastasis is an important cause of death. Epithelial mesenchymal transition (EMT) is an important factor in tumor cell metastasis, in which TGF-β signaling pathway plays an important role. SMAD7 can inhibit TGF-β pathway. Previously, we found that ovarian tumor domain-containing protein 3(OTUD3) could maintain the stability of multiple molecules through deubiquitination. In this study, multiple experiments were conducted to verify whether OTUD3 can inhibit TGF-β pathway by deubiquitinating SMAD7. Firstly, bioinformatics was used to search the expression of OTUD3 in breast cancer and its correlation with SMAD7 in the TCGA database. The correlation between the protein and mRNA expression levels of OTUD3 and SMAD7 in multiple BRCA cell lines was verified. Also, the OTUD3 and SMAD7 expression in human BRCA samples and its influence on prognosis were verified by immunohistochemical experiments. Then, the CO-IP experiment was performed by transfecting OTUD3 and SMAD7 in HEK293T cells to confirm whether OTUD3 could maintain SMAD7 protein stability through deubiquitination. Furthermore, luciferase reporting assay, in vitro protein interaction, and transwell assay were used to verify whether OTUD3 could inhibit TGF-β pathway by deubiquitinating SMAD7 and affect cell invasion. Western blot and RT-qPCR were used to detect the correlation between OTUD3 and molecules regulated by the TGF-β pathway. Finally, the effect of OTUD3 on tumor cells was determined by 3D matrigel cell culture. The expression of OTUD3 was low in BRCA and positively correlated with SMAD7. Cytological experiments and immunohistochemistry confirmed that OTUD3 was positively correlated with the expression of SMAD7, and the patients with a low expression of OTUD3 had a short recurrence-free survival (RFS). Cell experiments confirmed that OTUD3 could regulate the TGF-β pathway by deubiquitinating SMAD7, which affected EMT and inhibited cell invasion. OTUD3 was found to inhibit the stemness of tumor cells by 3D matrigel cell culture. Our findings indicated OTUD3 inhibited BRCA metastasis associated with TGF-β signaling by deubiquitination to stabilize SMAD7 protein levels.


  • Open Access

    The Novel Transcription Factor CREB3L4 Contributes to the Progression of Human Breast Carcinoma

    by Qian Pu, Li Lu, Ke Dong, Wen-Wen Geng, Yan-Rong Lv, Hai-Dong Gao

    Breast carcinoma(BC)is the most common cancer type among females globally. Understanding the molecular pathways that trigger the development of BC is crucial for both prevention and treatment. As such, the role of transcription factors (TFs) in the development of BC is a focal point in this field. CREB3s play a critical role in initiating the unfolded protein response (UPR); however, the role of CREB3 family members in breast cancer development remains largely unknown. Here, we mined the ONCOMINE database for the transcriptional data of CREB3s in patients with BC. Then, the regulatory functions of a novel TF, CREB3L4, were investigated. CREB3L4 knockdown in MDA-MB-231 and MCF-7 cells suppressed proliferation and promoted apoptosis and cell cycle arrest. ChIP assays confirmed that CREB3L4 can directly bind to the PCNA promoter region, suggesting that the PCNA protein may be functionally downstream of CREB3L4. Additionally, the expression level of CREB3L4 was assessed using our cohort. CREB3L4 is upregulated in breast cancer tissues and is significantly associated with histological grade and tumour size (P = 0.001 andP < 0.001, respectively). Furthermore, PCNA expression was upregulated in breast cancer tissues and positively correlated with CREB3L4. In summary, CREB3L4 may play an important role in the progression of human BC and may serve as a therapeutic target.


  • Open Access

    miR‐520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3‐PTEN Axis in Breast Cancer

    by Wenwen Geng, Haiyun Song, Qianqian Zhao, Ke Dong, Qian Pu, Haidong Gao, Yanrong Lv

    MicroRNAs (miRNAs) have been identified as negative posttranscriptional regulators of target genes and are involved directly in the pathological processes of tumors, including drug resistance. However, the exact function of miR‐520h in breast cancer remains poorly understood. The aim of this study was to investigate the molecular mechanisms of miR‐520h in paclitaxel resistance in the MCF‐7 breast cancer cell line. Ectopic expression of miR‐520h could promote the proliferation of breast cancer cells and inhibit paclitaxel‐induced cell apoptosis. Inhibiting the expression of miR‐520h could enhance the sensitivity to paclitaxel in paclitaxel‐resistant MCF‐7/Taxol cells. Furthermore, luciferase reporter assays showed that OTUD3 was a direct target of miR‐520h. OTUD3 plays a necessary role in the paclitaxel resistance effect of miR‐520h, and cotreatment with a miR‐520h inhibitor and OTUD3 overexpression significantly enhanced MCF‐7 cell sensitivity to paclitaxel. Moreover, miR‐520h substantially inhibited the protein expression of PTEN via OTUD3 and subsequently affected downstream p‐AKT pathway activity. In a clinical study, we also found that high miR‐520h expression was associated with more aggressive pathological characteristic and poor prognosis. Therefore, our findings showed that miR‐520h targeted the OTUD3‐PTEN axis to drive paclitaxel resistance, and this miR might be an important potential target for breast cancer treatment.